Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models

[1]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[2]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[3]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .

[4]  J. Whitty,et al.  A Cost-Utility Analysis of Prostate Cancer Screening in Australia , 2017, Applied Health Economics and Health Policy.

[5]  David Gillatt,et al.  Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. , 2016, The New England journal of medicine.

[6]  Karl Claxton,et al.  Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. , 2016, Health economics.

[7]  M. Cooperberg,et al.  Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies , 2022 .

[8]  R. Edlin,et al.  Economic evaluation of prostate cancer screening: a systematic review. , 2015, Future oncology.

[9]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[10]  Ruth Etzioni,et al.  Is prostate cancer screening cost‐effective? A microsimulation model of prostate‐specific antigen‐based screening for British Columbia, Canada , 2014, International journal of cancer.

[11]  M. Stockler,et al.  Risk assessment to guide prostate cancer screening decisions: a cost‐effectiveness analysis , 2013, The Medical journal of Australia.

[12]  Chris Metcalfe,et al.  Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study , 2012, BMJ : British Medical Journal.

[13]  Christina Bougatsos,et al.  Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.

[14]  G. Andriole,et al.  Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. , 2011, The Journal of urology.

[15]  E. Tacconelli.  Systematic reviews: CRD's guidance for undertaking reviews in health care , 2010 .

[16]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[17]  H. Yasunaga,et al.  Economic evaluation of prostate cancer screening with prostate‐specific antigen , 2008, International journal of urology : official journal of the Japanese Urological Association.

[18]  K. Mitsumori,et al.  Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  M Sculpher,et al.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment. , 2004, Health technology assessment.

[20]  A. Auvinen,et al.  Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. , 2015, Journal of the National Cancer Institute.

[21]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[22]  S. Taneja,et al.  Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. , 2015, The Journal of urology.

[23]  L. Cipriano,et al.  Guidelines for the Economic Evaluation of Health Technologies: Canada , 2012 .

[24]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[25]  C. Lawton,et al.  Screening and Prostate-Cancer Mortality in a Randomized European Study , 2010 .

[26]  Akers,et al.  Systematic Reviews [ressource électronique]. CRD's guidance for undertaking reviews in health care , 2009 .

[27]  Guidelines for the Economic Evaluation of Health Technologies in Ireland 2014 , 2022 .